Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.

MLA

Cai, Liang, et al. “Treatment Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma Patients with Arterioportal Fistula.” Cancer Biology & Therapy, vol. 23, no. 1, Dec. 2022, pp. 89–95. EBSCOhost, https://doi.org/10.1080/15384047.2021.2020059.

APA

Cai, L., Li, H., Guo, J., Zhao, W., Duan, Y., Hou, X., Cheng, L., Du, H., Shao, X., Diao, Z., Hao, Y., Zheng, X., Li, C., & Li, W. (2022). Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula. Cancer Biology & Therapy, 23(1), 89–95. https://doi.org/10.1080/15384047.2021.2020059

Chicago

Cai, Liang, Honglu Li, Jiang Guo, Wenpeng Zhao, Youjia Duan, Xiaopu Hou, Long Cheng, et al. 2022. “Treatment Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma Patients with Arterioportal Fistula.” Cancer Biology & Therapy 23 (1): 89–95. doi:10.1080/15384047.2021.2020059.